Today, Oculis Holding AG (Nasdaq: OCS) rings the Nasdaq opening bell in celebration of its public listing on the Nasdaq Stock Market! Oculis is a global biopharmaceutical company that is determined to save sight and improve eye care. As the bell is rung, let us all take a moment to recognize their efforts and celebrate this momentous occasion.
Oculis is revolutionizing the way we treat eye conditions by advancing its late clinical-stage product candidates. Its pipeline of highly differentiated treatments includes OCS-01, a topical eye drop for diabetic macular edema, OCS-02, a topical eye drop biologic for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophthalmic disorders. With these innovative treatments, Oculis is providing new hope for individuals suffering from eye conditions.
Oculis is proud to be supported by some of the most prominent names in healthcare investing, including funds managed by LSP, Earlybird, Novartis Venture Fund, Tekla Capital Management LLC, Pivotal Life Sciences, and VI Partners. With the invaluable backing of these investors, Oculis is set to achieve its mission and deliver upcoming near-term clinical milestones.
At 9.15am EDT, join Oculis’ Chief Executive Officer, Riad Sherif MD, as well as other members of the executive team, Board of Directors, Scientific Advisory Board members, and special guests for a live ceremony to celebrate the company’s achievements. This is an event you won’t want to miss!
Today, Oculis is ringing the opening bell in celebration of our Nasdaq public listing, made possible through the incredible support of our investors, partners and employees. This major corporate milestone provides us with a strong financial foundation to advance our clinical programs in ophthalmology, including treatments for retina, dry eye, and neuro-ophtha diseases such as acute optic neuritis and glaucoma.
We are thrilled to have achieved last-patient-last-visit in our Stage 1 Phase 3 DIAMOND study of OCS-01 eye drop in diabetic macular edema, with results expected shortly. We have also completed enrollment in our OCS-01 Phase 3 OPTIMIZE study for the treatment of inflammation and pain following cataract surgery, with results expected later this year.
I am delighted to announce the successful completion of the business combination and Oculis’ entry onto the Nasdaq Stock Market. On behalf of the Board of Directors, I would like to extend a warm welcome to our new colleagues, thank our former Board members for all their hard work, and look forward to collaborating with the new Board and wider team to bring innovative ophthalmic therapies to patients and generate value for shareholders.
Oculis is on a mission to save sight and improve eye care worldwide. Our highly differentiated pipeline consists of multiple innovative product candidates, such as OCS-01, a topical eye drop retinal candidate for diabetic macular edema; OCS-02, a topical eye drop biologic candidate for dry eye disease; and OCS-05, a disease-modifying candidate for acute optic neuritis and other neuro-ophthalmologic disorders.
Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis is determined to provide life-changing treatments to patients all over the world. Our experienced management team and leading international healthcare investors make this dream a reality. Join us on our mission to bring sight back to people!